Following the positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in the treatment of pneumonia in COVID-19 patients at risk of respiratory failure, Biophytis management is inviting all of Biophytis’ stakeholders to an online event with KOL.
Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19 Biophytis released the full results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure. A reduction in the risk of early death or respiratory failure at…
Biophytis publishes its key financial figures as at 30 June 2022, announces a restatement of the financial statements published as of December 31st, 2021 and provides an update on the operational milestones Fullscreen Mode
Biophytis announces receipt of Nasdaq Notice Biophytis announced that it has received written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) dated October 20, 2022, indicationg that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares (“ADSs”) for the prior 30 consecutive business…
Biophytis participates in H.C. Wainwright 24th Annual Global Investment Conference Biophytis made a presentation to investors on the 12th of September in New York, on the occasion of the 24th Global Investment Conference organised by the HC Wainwright bank, which is being held from 12 to 14 September 2022 in New York. During this oral…
Biophytis announces that on the 8th of September 2022 the Paris Court of Appeal rendered a decision in the case between Biophytis and Negma Group Ltd.
Biophytis released top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure
Biophytis to update on the development of Sarconeos (BIO101) in Covid-19 at the 4th Annual Longevity Therapeutics Summit Phase 2-3 COVA study results expected in Q3 2022 Biophytis announces its CEO, Stanislas Veillet, PhD, has been hosting a presentation at the 4th Annual Longevity Therapeutics Summit in San Francisco. The Biophytis presentation entitled “Discussing the…
Biophytis announces the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million Biophytis announces the issuance of the 160 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €4 million under its existing convertible bond agreement with Atlas, a specialized investment fund based…
Biophytis presents the development of Sarconeos (BIO101) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress Biophytis announced that it is giving an oral presentation on the development of Sarconeos (BIO101) for the treatment of sarcopenia at the 15th International SCWD Congress (Society on Sarcopenia, Cachexia & Wasting disorders). This…